Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Graft vs Host Disease 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 9Cyclophosphamide 9Whole-Body Irradiation 8Mycophenolic Acid 8Cyclosporine 8Cord Blood Stem Cell Transplantation 7fludarabine 5Peripheral Blood Stem Cell Transplantation 4Busulfan 4Arsenic Trioxide 4Antilymphocyte Serum 4Transplantation 3Thiotepa 3Tacrolimus 3Radiotherapy 3Etoposide 3Cytarabine 3Methylprednisolone 2Methotrexate 2Melphalan 2Carmustine 2Azacitidine 2thymoglobulin 1lonafarnib 1lintuzumab 1itacitinib 1Vorinostat 1Tretinoin 1Tetradecanoylphorbol Acetate 1Teriparatide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia, Refractory, with Excess of Blasts × Calcineurin Inhibitors × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡